Sodium Valproate in Schizophrenia: Some Biochemical Correlates
- 1 September 1980
- journal article
- research article
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 137 (3), 240-244
- https://doi.org/10.1192/bjp.137.3.240
Abstract
Summary: Sodium valproate given in doses of 750–3000 mg daily to eight schizophrenic patients produced a qualitatively similar increase in symptoms in five. CSF showed no significant change in γ-aminobutyric acid or methoxy hydroxyphenyl glycol, but homovanillic acid increased non-significantly in five patients.This publication has 17 references indexed in Scilit:
- Biochemical pharmacology of Gabaergic agonistsLife Sciences, 1979
- Influence of GABA-agonists and antagonists on neuroleptic-induced catalepsy in ratsLife Sciences, 1978
- Sodium Valproate and Tardive DyskinesiaThe British Journal of Psychiatry, 1978
- Research Diagnostic CriteriaArchives of General Psychiatry, 1978
- Specific and sensitive method for the determination of γ-aminobutyric acid using gas chromatography with electron-capture or mass fragmentographic detectionJournal of Chromatography A, 1977
- Effect of muscimol, a gaba-mimetic agent, on dopamine metabolism in the mouse brainLife Sciences, 1977
- Monoamine and GABA metabolism and the anticonvulsant action of DI-n-propylacetate and ethanolamine-O-sulphateEuropean Journal of Pharmacology, 1977
- Sodium ValproateDrugs, 1977
- Effect of Sodium Valproate on Tardive DyskinesiaThe British Journal of Psychiatry, 1976
- BACLOFEN IN SCHIZOPHRENIAThe Lancet, 1976